PatriciaL.LugarMD

Internal Medicine • Durham, NC

Allergy & Immunology

Associate Professor, Medicine, Duke University School of Medicine

Join to view full profile

Dr. Lugar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lugar's full profile

Already have an account?

Office
2100 Erwin Rd
Durham, NC 27705
Phone+1 919-684-8111

Summary

Associate Professor at Duke University in the Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine. My schedule is split between clinical care, clinical trials and translational research. I focus on rare disorders primarily immune deficiency. My research is aimed at improving diagnostics, therapeutics, and quality of life for patients with immune deficiency.

Education & Training

NIH Clinical CenterPost-Doctoral Fellowship, 2005 - 2007
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 2003 - 2005
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1999 - 2002
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1999
SUNYAB, Roswell Park Cancer InstituteMS, Molecular Medicine, 1996 - 1998

Certifications & Licensure

NC State Medical License 2007 - 2025
DC State Medical License 2002 - 2008
MD State Medical License 2003 - 2004

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants Start of enrollment: 2014 May 14
Completed
Phase 1
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Start of enrollment: 2016 Mar 03
Completed
Phase 3
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Start of enrollment: 2016 May 26
Completed
Phase 3
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) Start of enrollment: 2017 Feb 01
Completed
Phase 4
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE Start of enrollment: 2018 Feb 06
Completed
Phase 3
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America Start of enrollment: 2019 Mar 30
Completed
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II Start of enrollment: 2019 Dec 11
Active, not recruiting
Join now to see all

Publications & Presentations

PubMed

17 citations
Evaluation of a Pharmacist-Led Penicillin Allergy Assessment Program and Allergy Delabeling in a Tertiary Care Hospital.
Nicholas A Turner, Rebekah Wrenn, Christina Sarubbi, Renee Kleris, Patricia L. Lugar
JAMA Network Open. 2021-05-03
39 citations
Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial.
Ana Maria Copaescu, Sara Vogrin, Fiona James, Kyra Y L Chua, Morgan T Rose
JAMA Internal Medicine. 2023-09-01
166 citations
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs
Dereje D. Jima, Jenny Zhang, Cassandra L. Jacobs, Kristy L. Richards, Cherie H. Dunphy
Blood. 2010-12-02

Authored Content

CME: Biologics in the Treatment of Adults With T2-High, Uncontrolled AsthmaMay 2020
Women’s Health and Primary Immunodeficiency DiseasesJanuary 2020
PI and Womens Health: A Focus on Pregnancy and BeyondJuly 2018

Professional Memberships

American Academy of Allergy Asthma and Immunology - AAAAI
Member